

PUBBLICAZIONI SCIENTIFICHE 2018 DEL CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI, FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIOR POLICLINICO									
	TITOLO PAPER	AUTORI	RIVISTA	ANNO	VOLUME	ISSUE	PAGINE	DOI	TIPO DI PUBBLICAZIONI
1	Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients.	Agosti P, Tettamanti M, Vella FS, Supressa P, Pasina L, Franchi C, Nobili A, Mannucci PM, Sabbà C; REPOSI Investigators (Peyvandi F, Rossio R, Ferrari).	European Journal of Internal Medicine	2018	57	-	25 - 31	10.1016/j.ejim.2018.06.014	Multicentrico Collaborators
2	Recombinant Factor XIII-A in a Patient with Factor XIII Deficiency and Recurrent Pregnancy Loss.	Al-Khabori M, Pathare A, Menegatti M, Peyvandi F.	Journal of Thrombosis and Haemostasis	2018	16	6	1052 - 1054	10.1111/jth.14126	Case Report
3	Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.	Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetti E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, Cugno M.	Pediatric Nephrology	2018	33	3	457 - 461	10.1007/s00467-017-3813-2	Articolo originale
4	Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis.	Artoni A, Abbattista M, Buccarella P, Gianniello F, Scalambriano E, Pappalardo E, Peyvandi F, Martinelli I.	Clinical and Applied Thrombosis/Hemostasis	2018	24	5	808 - 814	10.1177/1076029617733039	Articolo originale
5	Hemostatic abnormalities in patients with ehlers-danlos syndrome.	Artoni A, Bassotti A, Abbattista M, Marinelli B, Lechci A, Gianniello F, Clerici M, Buccarella P, La Marca S, Peyvandi F, Martinelli I	Journal of Thrombosis and Haemostasis	2018	16	12	2425 - 2431	10.1111/jth.14310	Articolo originale
6	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.	Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.	Research and Practice in Thrombosis and Haemostasis	2018	2	3	407 - 428	10.1002/rth2.12095	Review
7	Fifth Åland Island conference on von Willebrand disease.	Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, Federici AB, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J.	Haemophilia	2018	24	Suppl 4	5 - 19	10.1111/hae.13475	Review
8	Acquired Von Willebrand syndrome and response to desmopressin	Biguzzi E, Siboni SM, Peyvandi F	Haemophilia	2018	24	1	e25 - e28	10.1111/hae.13382	Lettera con dati
9	Coagulation, Microenvironment and Liver Fibrosis.	Bitto N, Liguori E, La Mura V	Cells	2018	7	8	85	10.3390/cells7080085	Review
10	Ageing successfully with haemophilia: A multidisciplinary programme.	Boccalandro E, Mancuso ME, Riva S, Pisaniello DM, Ronchetti F, Santagostino E, Peyvandi F, Solimeno LP, Mannucci PM, Pasta G.	Haemophilia	2018	24	1	57 - 62	10.1111/hae.13308	Articolo originale
11	Stormorken Syndrome Caused by a p.R304W STIM1 Mutation: The First Italian Patient and a Review of the Literature.	Borsani O, Piga D, Costa S, Govoni A, Magri F, Artoni A, Cinnante CM, Fagioli G, Ciscato P, Moggio M, Bresolin N, Comi GP, Corti S.	Frontiers in Neurology	2018	9	eCollection2018	859	10.3389/fneur.2018.00859	Articolo originale
12	Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel S von Willebrand multimer, by two European Centers	Bowyer AE, Goodfellow KJ, Seidel H, Westhofen P, Stufano F, Goodeve A, Kitchen S, Makris M	Research and Practice in Thrombosis and Haemostasis	2018	2	4	790 - 799	10.1002/rth2.12141	Articolo originale
13	"In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate.	Bulato C, Novembrino C, Anzoletti MB, Spiezia L, Gavasso S, Berbenni C, Tagariello G, Farina C, Nardini I, Campello E, Peyvandi F, Simioni P	Haemophilia	2018	24	4	648 - 656	10.1111/hae.13465	Articolo originale
14	Cerebral venous sinus thrombosis.	Capecchi M, Abbattista M, Martinelli I.	Journal of Thrombosis and Haemostasis	2018	16	10	1918 - 1931	10.1111/jth.14210	Review
15	What is behind a relapse of thrombotic thrombocytopenic purpura?	Capecchi M, Artoni A, Cappellini MD, Graziaidei G.	Internal and Emergency Medicine	2018	13	5	709 - 712	10.1007/s11739-017-1764-z	Case Report
16	Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis	Caraco M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L; International Prophylaxis Study Group (IPSG).	Haemophilia	2018	24	6	845 - 848	10.1111/hae.13558	Lettera con dati
17	Risk of post-operative venous thromboembolism in patients with meningioma.	Carrabba G, Riva M, Conte V, Di Cristofori A, Caroli M, Locatelli M, Castellani M, Buccarella P, Artoni A, Stocchetti N, Martinelli I, Rampini P.	Journal of Neuro-Oncology	2018	138	2	401 - 406	10.1007/s11060-018-2810-z	Articolo originale
18	Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH.	Casini A, Undas A, Palla R, Thachil J, de Moerloose P; Subcommittee on Factor XIII and Fibrinogen.	Journal of Thrombosis and Haemostasis	2018	16	9	1887 - 1890	10.1111/jth.14216	Multicentrico NO Profit
19	Recurrent Bleedings in Newborn: A Factor VII Deficiency Case Report.	Cattivelli K, Distefano C, Bonetti L, Testa S, Siboni SM, Plebani A, Poggiani C.	Transfusion Medicine and Hemotherapy	2018	45	2	104 - 106	10.1159/000481993	Case Report
20	Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register.	Cesari M, Franchi C, Cortesi L, Nobili A, Ardoino I, Mannucci PM; REPOSI collaborators (Peyvandi F, Rossio R).	European Journal of Internal Medicine	2018	56		11 - 18	10.1016/j.ejim.2018.06.001	Multicentrico Collaborators
21	Diagnosis and Management of the Antiphospholipid Syndrome.	Clavarella A, Martinelli I.	New England Journal of Medicine	2018	379	13	1289 - 1289	10.1056/NEJMc1808253	Lettera opinion
22	Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register.	Cini M, Legnani C, Cosmi B, Testa S, Dellanoce C, Paoletti O, Marcucci R, Poli D, Paniccia R, Pengo V, Tripodi A, Palareti G; START-Laboratory Register	International Journal of Laboratory Hematology	2018	40	2	229 - 236	10.1111/ijlh.12772	Multicentrico NO Profit
23	Electrocardiographic diagnosis: When QRS is wide [Diagnostica elettrocardiografica: quando il QRS è largo]	Conti M., Bregani E.R.	Recenti Progressi in Medicina	2018	109	4	236 - 241	10.1701/2896.29195	Articolo originale

24	Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).	Coppola A, Franchini M, Castaman G, <b>Santagostino E</b> , Santoro C, Santoro RC, Morfini M, Di Minno G, Rocino A; <b>AICE ad hoc Working Group (Mancuso ME)</b> .	Seminars in Thrombosis and Hemostasis	2018	44	6	551 - 560	10.1055/s-0038-1648230	Multicentrico NO Profit
25	Prevalence, characteristics and treatment of chronic pain in elderly patients hospitalized in internal medicine wards.	Corsi N, Roberto A, Cortesi L, Nobili A, Mannucci PM, Corli O; <b>REPOSI Investigators (Peyvandi F, Rossio R, Ferrari B)</b>	European Journal of Internal Medicine	2018	55		35 - 39	10.1016/j.ejim.2018.05.031	Multicentrico Collaborators
26	Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria.	<b>Cugno M</b> , Asero R, Ferrucci S, Lorini M, Carbonelli V, Tedeschi A, Marzano AV.	Allergy	2018	73	12	2408 - 2411	10.1111/all.13587	Lettera con dati
27	Validation of the Predictive Model of the European Society of Cardiology for Early Mortality in Acute Pulmonary Embolism	<b>Cugno M</b> , Depetri F, Gnocchi L, Porro F, <b>Bucciarelli P</b>	TH Open	2018	2	3	e265 - e271	10.1055/s-0038-1669427	Articolo originale
28	IgE and D-dimer baseline levels are higher in responders than non-responders to omalizumab in chronic spontaneous urticaria.	<b>Cugno M</b> , Genovese G, Ferrucci S, Casazza G, Asero R, Marzano AV.	British Journal of Haematology	2018	179	3	776 - 777	10.1111/bjhd.16593	Lettera con dati
29	Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.	<b>Cugno M</b> , Gualtierotti R, Meroni PL, Marzano AV.	Clinical Reviews in Allergy & Immunology	2018	54	2	269 - 281	10.1007/s12016-017-8629-0.	Review
30	Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes.	de Haan HG, van Hylckama Vlieg A, Lotta LA, <b>Gorski MM, Buccicarelli P, Martinelli I; INVENT consortium</b> , Baglin TP, <b>Peyvandi F</b> , Rosendaal FR.	Journal of Thrombosis and Haemostasis	2018	16	12	2432 - 2441	10.1111/jth.14279	Multicentrico NO Profit
31	Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2 DS2 VASc 1 or 2): A treatment dilemma.	Denas G, Zopplaro G, Padayattil Jose S, Antonucci E, Marongiu F, Poli D, Testa S, <b>Tripoli A</b> , Palareti G, Pengo V.	Cardiovascular Therapeutics	2018	36	1	e12310	10.1111/1755-5922.12310	Articolo originale
32	An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia	Depetri F, <b>Cugno M</b> , Graziadei G, Di Pierro E, Granata F, <b>Peyvandi F</b> , Cappellini MD	Internal and Emergency Medicine	2018	13	8	1233 - 1238	10.1007/s11739-018-1826-x	Case Report
33	Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis/activity.	Donadon I, McVey JH, <b>Garagiola I</b> , Branchini A, <b>Mortarino M, Peyvandi F</b> , Bernardi F, Pinotti M	Haematologica	2018	103	2	344 - 350	10.3324/haematol.2017.178327	Articolo originale
34	The ISTH Bleeding Assessment Tool and the risk of future bleeding.	<b>Fasulo MR, Biguzzi E, Abbattista M, Stefano F, Pagliari MT, Mancini I, Gorski MM, Cannavò A, Corgioli M, Peyvandi F</b> , Rosendaal FR.	Journal of Thrombosis and Haemostasis	2018	16	1	125 - 130	10.1111/jth.13883	Articolo originale
35	Major hemorrhages in patients treated with oral anticoagulants: choice of management in the emergency room.	Folli C, Casiraghi C, <b>Braham S</b> , Rovellini A, Monzani V.	European Journal of Internal Medicine	2018	55	-	e25 - e26	10.1016/j.ejim.2018.07.017	Lettera con dati
36	Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation	Franchi C, Antoniazzi S, Proietti M, Nobili A, Mannucci PM; <b>SIM-AF Investigators (Peyvandi F, Rossio R)</b>	British Journal of Clinical Pharmacology	2018	84	9	2010 - 2019	10.1111/bcp.13631	Multicentrico Collaborators
37	Haemophilia B is clinically less severe than haemophilia A: further evidence.	Franchini M, <b>Mannucci PM</b> .	Blood Transfusion	2018	16	2	121 - 122	10.2450/2016.0158-16.	Lettera opinion
38	Alloantibodies in von Willebrand Disease.	Franchini M, <b>Mannucci PM</b> .	Seminars in Thrombosis and Hemostasis	2018	44	6	590 - 594	10.1055/s-0037-1607440	Review
39	Primary hyperfibrinolysis: Facts and fancies.	Franchini M, <b>Mannucci PM</b> .	Thrombosis Research	2018	166	/	71 - 75	10.1016/j.thromres.2018.04.010	Review
40	The importance of ABO blood group in pharmacokinetic studies in haemophilia A.	Franchini M, Mengoli C, Marano G, Pupella S, <b>Mannucci PM</b> , Liembruno GM.	Haemophilia	2018	24	3	e122 - e123	10.1111/hae.13437	Lettera con dati
41	Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss.	Frattini E, Monfrini E, Bitetto G, <b>Ferrari B</b> , Arcudi S, Bresolin N, Saetti MC, Di Fonzo A.	Neurology	2018	90	12	572 - 575	10.1212/WNL.00000000005177	Case Report
42	Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients.	Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV, Picardi A, <b>Mannucci PM</b> , Incalzi RA; <b>REPOSI Investigators (Peyvandi F, Rossio R, Ferrari B)</b>	European Journal of Internal Medicine	2018	54	-	60 - 64	10.1016/j.ejim.2018.04.001	Multicentrico NO Profit
43	Risk factors for inhibitor development in severe hemophilia a.	<b>Garagiola I, Palla R, Peyvandi F</b> .	Thrombosis Research	2018	168	-	20 - 27	10.1016/j.thromres.2018.05.027	Review
44	The intra-assay reproducibility of thromboelastography in very low birth weight infants.	Ghirardello S, Raffaelli G, <b>Scalambrino E, Chantarangkul V</b> , Cavallaro G, <b>Artoni A</b> , Mosca F, <b>Tripoli A</b> .	Early Human Development	2018	127	December 2018	48 - 52	10.1016/j.earlhumdev.2018.10.004	Articolo originale
45	European principles of inhibitor management in patients with haemophilia.	Giangrande PLF, Hermans C, O'Mahony B, de Kleijn P, Bedford M, Batorova A, Blatný J, Jansone K; <b>European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD) (F. Peyvandi)</b>	Orphanet Journal of Rare Diseases	2018	13	1	66	10.1186/s13023-018-0800-z	Multicentrico Collaborators

46	Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis.	Gorski MM, de Haan HG, Mancini I, Lotta LA, Bucciarelli P, Passamonti SM, Cairo A, Pappalardo E, van Hylckama Vlieg A, Martinelli I, Rosendaal FR, Peyvandi F.	Thrombosis Research	2018	169	-	76 - 81	10.1016/j.thromres.2018.06.011	Articolo originale
47	Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.	Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S; <b>Marzeptacog alfa (activated) Study Group Investigators (Santagostino E, Cannavò A, Fasulo MR, Mancuso ME)</b>	Journal of Thrombosis and Haemostasis	2018	16	10	1984 - 1993	10.1111/jth.14247	Multicentrico Collaborators
48	Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases.	Gualtierotti R, Marzano AV, Spadari F, Cugno M.	Journal of Clinical Medicine	2018	8	1	21	10.3390/jcm8010021	Review
49	Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.	Hassan S, <b>Cannavò A</b> , Gouw SC, Rosendaal FR, van der Bom JG.	Journal of Thrombosis and Haemostasis	2018	16	6	1055 - 1068	10.1111/jth.14124	Review
50	Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.	Hermans C, Mahlangu J, Booth J, Schütz H, <b>Santagostino E</b> , Young G, Lee HY, Steinitz-Trost KN, Blanchette V, Berntorp E.	Haemophilia	2018	24	3	376 - 384	10.1111/hae.13483	Articolo originale
51	Factor XIII deficiency diagnosis: Challenges and tools.	Karimi M, <b>Peyvandi F</b> , Naderi M, Shapiro A.	International Journal of Laboratory Hematology	2018	40	1	3 - 11	10.1111/ijlh.12756	Review
52	Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.	Khair K, Mazzucconi MG, Parra R, <b>Santagostino E</b> , Tsakiris DA, Hermans C, Oldenburg J, Spotts G, Steinitz-Trost K, Gringeri A.	Haemophilia	2018	24	1	85 - 96	10.1111/hae.13361	Multicentrico Profit
53	Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study.	Kubitzka D, Willmann S, Becka M, Thelen K, Young G, Brandão LR, Monagle P, Male C, Chan A, Kennet G, <b>Martinelli I</b> , Saracco P, Lensing AWA.	Thrombosis Journal	2018	16	eCollection 2018	31	10.1186/s12959-018-0186-0	Articolo originale
54	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis.	<b>La Mura V, Brahams S</b> , Tosetti G, Branchi F, Bitto N, <b>Moia M</b> , Fracanzani AL, Colombo M, <b>Tripodi A</b> , Primignani M.	Clinical Gastroenterology and Hepatology	2018	16	7	1146 - 1152	10.1016/j.cgh.2017.10.016	Articolo originale
55	Practical aspects of extended half-life products for the treatment of haemophilia.	Lambert T, Benson G, Dolan G, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Zupancic Šalek S, <b>Santagostino E</b> .	Therapeutic Advances in Hematology	2018	9	9	295 - 308	10.1177/2040620718796429	Review
56	Use of fresh-frozen plasma in 2012 at the Fondazione Ca' Granda Hospital of Milan: assessment of appropriateness using record linkage techniques applied to data routinely recorded in various hospital information systems.	Lanzoni M, Olivero B, <b>Artoni A</b> , Marconi M, Raspollini E, Castaldi S.	Blood Transfusion	2018	16	3	253 - 261	10.2450/2017.0309-16	Articolo originale
57	Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL)—guidelines for laboratory detection of Lupus Anticoagulant (LA) [La ricerca del lupus anticoagulante: raccomandazioni del gruppo di studio sulla coagulazione di SIPMeL]	Legnani C, Martini G, Bertini M, Agostini P., Bondanini F., Cozzi M.R., Demicheli M.S.A., Di Felice G., Novembri C., Paoletti O., Pedrini S., Ruocco L., Steffan A., Terzuoli L., Testa S.	Rivista Italiana della Medicina di Laboratorio	2018	14	3	156 - 164	10.1007/s13631-018-0185-y	Articolo originale
58	Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.	Lentz SR, Janic D, Kavaklı K, Miljic P, Oldenburg J, C Ozelo M, <b>Santagostino E</b> , Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.	Haemophilia	2018	24	6	e391 - e394	10.1111/hae.13617	Articolo originale
59	Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.	Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavaklı K, De Angulo GR, Almomen A, Schwartz BA, Solomon C, Knaub S, <b>Peyvandi F</b> .	Transfusion	2018	58	2	413 - 422	10.1111/trf.14421	Articolo originale
60	Desmopressin in moderate hemophilia A patients: a treatment worth considering.	Loomans JL, Kruij MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, <b>Santagostino E</b> , Platokouki H, Beckers E, Voorberg J, van der Bom JG, Fijnvandraat K <b>RISE consortium</b> .	Haematologica	2018	103	3	550 - 557	10.3324/haematol.2017.180059	Multicentrico NO Profit
61	Anticoagulation Knowledge Tool (AKT): Further evidence of validity in the Italian population.	Magon A, Arrigoni C, Roveda T, Grimoldi P, Dellafiore F, <b>Moia M</b> , Obamiro KO, Caruso R	PLoS One	2018	13	8	e0201476 - -	10.1371/journal.pone.0201476	Articolo originale
62	Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.	Mahlangu J, Oldenburg J, Callaghan MU, Shima M, <b>Santagostino E</b> , Moore M, Recht M, García C, Yang R, Lehle M, Macharia H, Asikianus E, Levy GG, Kruse-Jarres R.	Haemophilia	2018	24	6	921 - 929	10.1111/hae.13612	Articolo originale
63	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.	Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, <b>Mancuso ME</b> , Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JL, Asikianus E, Levy GG, Kruse-Jarres R	New England Journal of Medicine	2018	379	9	811 - 822	10.1056/NEJMoa1803550.	Articolo originale
64	Defining extended half-life rFVIII-A critical review of the evidence.	Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, <b>Santagostino E</b> .	Haemophilia	2018	24	3	348 - 358	10.1111/hae.13438	Review
65	The predictive value of factor VII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH.	<b>Mancuso ME</b> , Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A; <b>subcommittee on factor viii, factor ix and rare coagulation disorders.</b>	Journal of Thrombosis and Haemostasis	2018	16	10	2106 - 2110	10.1111/jth.14257	Multicentrico NO Profit
66	Viral safety of coagulation factor concentrates: memoirs from an insider.	<b>Mannucci PM</b>	Journal of Thrombosis and Haemostasis	2018	16	4	630 - 633	10.1111/jth.13963	Commento

67	How to win space in medical journals: Bits and tips.	Mannucci PM	European Journal of Internal Medicine	2018	50	/	1 - 2	10.1016/j.ejim.2018.02.007	Editoriale
68	Miracle of haemophilia drugs: Personal views about a few main players.	Mannucci PM	Haemophilia	2018	24	4	557 - 562	10.1111/hae.13519	Review
69	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls.	Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, <b>Peyvandi F</b> , Iorio A.	Haemophilia	2018	24	5	726 - 732	10.1111/hae.13595	Articolo originale
70	Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register.	Mannucci PM, Nobili A, Pasina L; <b>REPOSI Collaborators</b> (REPOSI is the acronym of RÉgistré POLiterapie SIMI, Società Italiana di Medicina Interna). ( <b>Peyvandi F, Rossio R, Ferrari F</b> )	Internal and Emergency Medicine	2018	13	8	1191 - 1200	10.1007/s11739-018-1941-8	Review
71	Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population.	Marchesini E, Oliovecchio E, Coppola A, <b>Santagostino E</b> , Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Iorio A, Mannucci PM.	Haemophilia	2018	24	1	e6 - e10	10.1111/hae.13379	Lettera con dati
72	Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.	Mariani S, Trisolini SM, Capria S, Moleti ML, <b>Chisini M</b> , Ferrazza G, Bafti MS, Limongiello MA, Miulli E, <b>Peyvandi F</b> , Foà R, Testi AM	Haematologica	2018	103	3	e138 - e140	10.3324/haematol.2017.185363	Case Report
73	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban.	Martinelli I, Abbattista M, Buccarelli P, Tripodi A, Artoni A, Gianniello F, Novembrino C, <b>Peyvandi F</b> .	Haematologica	2018	103	7	e315 - e317	10.3324/haematol.2017.185132	Lettera con dati
74	A Comprehensive Review of Neutrophilic Diseases.	Marzano AV, Borghi A, Wallach D, <b>Cugno M</b> .	Clinical Reviews in Allergy & Immunology	2018	54	1	114 - 130	0.1007/s12016-017-8621-8	Review
75	LPIN2 gene mutation in a patient with overlapping neutrophilic disease (pyoderma gangrenosum and aseptic abscess syndrome).	Marzano AV, Ortega-Loayza AG, Ceccherini I, <b>Cugno M</b> .	JAAD Case Reports	2018	4	2	120 - 122	10.1016/j.jdcr.2017.08.020	Case Report
76	High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.	Messori A, <b>Peyvandi F</b> , Trippoli S, <b>Palla R</b> , Rosendaal FR, <b>Mannucci PM</b> .	Blood Transfusion	2018	16	2	215 - 220	10.2450/2017.0352-16	Articolo originale
77	Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.	Oldenburg J, Carcao M, Lentz SR, Mahlangu J, <b>Mancuso ME</b> , Matsushita T, Negrer C, Clausen WHO, Ehrenforth S, Young G.	Haemophilia	2018	24	6	911 - 920	10.1111/hae.13608	Articolo originale
78	The importance of inhibitor eradication in clinically complicated hemophilia A patients.	Oldenburg J, Young G, <b>Santagostino E</b> , Escribano Ettingshausen C.	Expert Review of Hematology	2018	11	11	857 - 862	10.1080/17474086.2018.1521718	Review
79	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study.	Paciullo F, Projetti M, Bianconi V, Nobili A, Pirro M, <b>Mannucci PM</b> , Lip GYH, Lupattelli G; <b>REPOSI Investigators</b> ( <b>Peyvandi F, Rossio R, Ferrari B</b> )	Drugs Aging	2018	35	4	365 - 373	10.1007/s40266-018-0532-8	Multicentrico NO Profit
80	Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation.	Pagliari MT, Baronciani L, Stufano F, Colpani P, Siboni SM, <b>Peyvandi F</b> .	Haemophilia	2018	24	4	e263 - e266	10.1111/hae.13532	Lettera con dati
81	Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study	Panigada M., E. Iapichino G., Brioni M., Panarello G., Protti A., Grasselli G., Occhipinti G., <b>Novembrino C.</b> , Consonni D., Arcadipane A., Gattinoni L., Pesenti A.	Annals of Intensive Care	2018	8	1	-	10.1186/s13613-017-0352-8	Articolo originale
82	Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study.	Pasina L, Cortesi L, Tiraboschi M, Nobili A, Lanzo G, Tettamanti M, Franchi C, <b>Mannucci PM</b> , Ghidoni S, Assolari A, Brucato A; <b>REPOSI Investigators</b> . ( <b>Peyvandi F, Rossio R</b> )	Archives of Gerontology and Geriatrics	2018	74	-	169 - 173	10.1016/j.archger.2017.10.016.	Multicentrico NO Profit
83	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.	Pengo V, Denas G, Zoppellaro G, Padayattil Jose S, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, <b>Martinelli I</b> , Testa S, Barcellona D, Gerosa M, Banzato A.	Blood	2018	132	13	1365 - 1371	10.1182/blood-2018-04-848333	Articolo originale
84	Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report.	<b>Peyvandi F</b>	Blood Transfusion	2018	16	-	326 - 328	10.2450/2017.0131-17.	Editoriale
85	Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.	<b>Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM</b> , Rosendaal FR; <b>SIPPET Study Group</b> ( <b>Santagostino E, Mancuso ME</b> )	Journal of Thrombosis and Haemostasis	2018	16	1	39 - 43	10.1111/jth.13888	Multicentrico NO Profit
86	Product type and other environmental risk factors for inhibitor development in severe hemophilia A.	<b>Peyvandi F, Garagiola I.</b>	Research and Practice in Thrombosis and Haemostasis	2018	2	2	220 - 227	10.1002/rth2.12094	Review
87	Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.	<b>Peyvandi F, Palla R, Franchi C, Nobili A, Rosendaal FR, Mannucci PM</b> .	Haemophilia	2018	24	4	e266 - e268	10.1111/hae.13535	Lettera con dati
88	First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries.	Pierce GF, Haffar A, Ampatzidis G, <b>Peyvandi F</b> , Diop S, El-Ekiaby M, van den Berg HM.	Haemophilia	2018	24	2	229 - 235	10.1111/hae.13409	Articolo originale

89	Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards.	Proietti M, Antoniazzi S, Monzani V, Santalucia P, Franchi C; <b>SIM-AF Investigators (Peyvandi F, Rossio R).</b>	European Journal of Internal Medicine	2018	52	-	e12 - e14	10.1016/j.ejim.2018.04.006	Multicentrico Collaborators
90	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.	Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davi G, Hiatt WR, Lip GH, Corazza GR, Perticone F, Violà F, Basilis S; <b>ARAPACIS Study Collaborators (Moia M, Braham S)</b>	Internal and Emergency Medicine	2018	13	5	651 - 660	10.1007/s11739-018-1835-9	Multicentrico Collaborators
91	Idealisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.	Reda G, Cassin R, Artoni A, Leccì A, Fattizzo B, <b>La Marca S, Buccarelli P, Peyvandi F, Cortelezzi A</b>	British Journal of Haematology	2018	183	5	825 - 828	10.1111/bjh.15052	Lettera con dati
92	The effect of recanalization on long-term neurological outcome after cerebral venous thrombosis.	Rezoagli E, <b>Martinelli I, Poli D, Scoditti U, Passamonti SM, Buccarelli P, Ageno W, Dentali F.</b>	Journal of Thrombosis and Haemostasis	2018	16	4	718 - 724	10.1111/jth.13954	Articolo originale
93	Molecular investigation of 41 patients affected by coagulation factor XI deficiency.	Rimoldi V, Paraboschi EM, <b>Menegatti M, Peyvandi F, Salomon O, Duga S, Asselta R</b>	Haemophilia	2018	24	2	e50 - e55	10.1111/hae.13378	Lettera con dati
94	Polypharmacy in older adults with severe haemophilia.	Riva S, <b>Mancuso ME, Cortesi L, Nobili A, Santagostino E, Peyvandi F, Mannucci PM.</b>	Haemophilia	2018	24	1	e1 - e3	10.1111/hae.13262	Lettera con dati
95	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.	Roose E, Vidarsson G, Kangro K, Verhagen OJHM, <b>Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K</b>	Thrombosis and Haemostasis	2018	118	10	1729 - 1742	10.1055/s-0038-1669459	Articolo originale
96	Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.	Ross C, Rangarajan S, Karimi M, Tooghe GH, Apte S, Lissitzkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz B, Knaub S, <b>Peyvandi F.</b>	Journal of Thrombosis and Haemostasis	2018	16	2	253 - 261	10.1111/jth.13923	Articolo originale
97	Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: a case report and literature review	<b>Rossio R, Arcudi S, Peyvandi F, Piconi S</b>	International Journal of Clinical Pharmacology and Therapeutics	2018	56	2	86 - 89	10.5414/CP203084	Case Report
98	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations.	Sangiiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, <b>La Mura V, Colombo M, Lampertico P.</b>	Liver International	2018	38	9	1624 - 1634	10.1111/liv.13888	Articolo originale
99	GlycoPEGylated recombinant factor IX for hemophilia B in context.	<b>Santagostino E, Mancuso ME</b>	Drug Design, Development and Therapy	2018	12	-	2933 - 2943	10.2147/DDT.S121743	Review
100	A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.	<b>Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S</b>	Expert Review of Hematology	2018	11	2	87 - 97	10.1080/17474086.2018.1419862	Review
101	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.	Sawhney JP, Kothiwale VA, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawla K, Allu J, Pieper KS, John Camm A, Kakkar AK; <b>GARFIELD-AF Investigators (Moia M).</b>	Indian Heart Journal	2018	70	6	828 - 835	10.1016/j.ihj.2018.09.001	Multicentrico Collaborators
102	Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem® device.	Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Biliou S, <b>Peyvandi F, Tripodi A.</b>	Thrombosis Research	2018	172	-	139 - 141	10.1016/j.thromr.2018.10.030	Lettera con dati
103	Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long term prophylaxis.	Schinco P, Castaman G, Coppola A, Cultrera D, Ettorre C, Giuffrida AC, Marchesini E, Marino R, Milan M, Molinari C, <b>Siboni SM, Zanon E, Federici AB.</b>	Blood Transfusion	2018	16	-	371 - 381	10.2450/2017.0354-16	Articolo originale
104	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis.	Senzolo M, Riva N, Dentali F, Rodriguez-Castro K, Sartori MT, Bang SM, <b>Martinelli I, Schulman S, Alatri A, Beyer-Westendorf J, Di Minno MND, Agno W; IRSVT study investigators.</b>	Clinical and Translational Gastroenterology	2018	9	8	76	10.1038/s41424-018-0043-2.	Multicentrico NO Profit
105	Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica.	Seuser A, Navarrete-Duran M, Auerswald G, <b>Mancuso ME.</b>	Haemophilia	2018	24	4	e230 - e241	10.1111/hae.13455	Articolo originale
106	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.	Simón-Talero M, Roccarino D, Martínez J, Lampichler K, Baiges A, Low G, Ulop E, Praktiknjo M, Maurer MH, Zipprich A, Triolo M, Vangrinsev G, García-Martínez R, Dam A, Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, Lopez M, Kukuk G, Krag A, Bañares R, Laleman W, <b>La Mura V, Ripoll C, Berzogotti A, Trebică JL, Tandon P, Hernández-Gea V, Reiberger T, Albillas A, Tsochatzis EA, Augustin S, Genescà J; Baveno VI-SPSS group from the Baveno Cooperation.</b>	Gastroenterology	2018	154	6	1694 - 1705	10.1053/j.gastro.2018.01.028	Articolo originale
107	Prediction of Factor VIII inhibitor development in the SIPPET cohort by mutational analysis and Factor VIII antigen measurement.	Spina S, Garagiola I, Cannavò A, Mortarino M, Mannucci PM, Rosendaal FR, <b>Peyvandi F; SIPPET Study Group (Santagostino E, Mancuso ME).</b>	Journal of Thrombosis and Haemostasis	2018	16	4	778 - 790	10.1111/jth.13961	Multicentrico NO Profit
108	A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.	Stufano F, Baronciani L, Mane-Padros D, Cozzi G, Faraudo S, <b>Peyvandi F</b>	Haemophilia	2018	24	1	156 - 161	10.1111/hae.13371	Articolo originale

109	An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.	Szederjesi A, <b>Baronciani L</b> , Budde U, Castaman G, Lawrie AS, Liu Y, Montgomery R, <b>Peyvandi F</b> , Schneppenheim R, Várkonyi A, Patzke J, Bodó I.	Journal of Thrombosis and Haemostasis	2018	16	8		10.1111/jth.14206	Articolo originale
110	Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians.	Tagliaferri A, Franchini M, Rivolta GF, Farace S, Quintavalle G, Coppola A; <b>ad hoc Study Group (Mancuso ME)</b> .	Haemophilia	2018	24	5	1604 - 1613 766 - 773	10.1111/hae.13600.	Multicentrico Collaborators
111	Low drug levels and thrombotic complications in high risk atrial fibrillation patients treated with direct oral anticoagulants.	Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, <b>Tripodi A</b> , Palareti G	Journal of Thrombosis and Haemostasis	2018	16	5	842 - 848	10.1111/jth.14001	Articolo originale
112	Response to Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy.	<b>Tripodi A</b>	Liver International	2018	38	1	186	10.1111/liv.13582.	Lettera opinion
113	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL	<b>Tripodi A</b> , Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Marcucci R, <b>Moia M</b> , Morelli B, Poli D, Steffan A, Testa S.	Blood Transfusion	2018	16	-	462 - 470	10.2450/2017.0124-17	Articolo originale
114	How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues.	<b>Tripodi A</b> , <b>Braham S</b> , <b>Scimeca B</b> , <b>Moia M</b> , <b>Peyvandi F</b>	Polish Archives of Internal Medicine	2018	128	6	379 - 385 428	10.20452/pamw.10.20452/pamw.428	Review
115	Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme	<b>Tripodi A</b> , <b>Chantarangkul V</b> , Legnani C, Testa S, Tosetto A.	Journal of Thrombosis and Haemostasis	2018	16	3	565 - 570	10.1111/jth.13949.	Articolo originale
116	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.	<b>Tripodi A</b> , Marongiu F, <b>Moia M</b> , Palareti G, Pengo V, Poli D, Prisco D, Testa S, Zanazzi M	Internal and Emergency Medicine	2018	13	7	1029 - 1036	10.1007/s11739-018-1854-6	Review
117	Usefulness of bone microarchitectural and geometric DXA-derived parameters in haemophilic patients.	Ulivieri FM, Rebagliati GAA, Piodi LP, Solimeno LP, Pasta G, Boccalandro E, <b>Fasulo MR</b> , <b>Mancuso ME</b> , <b>Santagostino E</b> .	Haemophilia	2018	24	6	980 - 987	10.1111/hae.13611	Articolo originale
118	International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain and for thromboplastin, recombinant, human, plain.	van den Besselaar AMHP, <b>Chantarangkul V</b> , Angeloni F, Binder NB, Byrne M, Dauer R, Gudmundsdottir BR, Jespersen J, Kitchen S, Legnani C, Lindahl TL, Manning RA, Martinuzzo M, Panes O, Pengo V, Riddell A, Subramanian S, Szederjesi A, Tantanate C, Herbel P, <b>Tripodi A</b>	Journal of Thrombosis and Haemostasis	2018	16	1	142 - 149	10.1111/jth.13879	Articolo originale
119	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.	Verheugt FWA, Gao H, Al Mahmood W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK; <b>GARFIELD-AF Investigators (Moia M)</b> .	European Heart Journal	2018	39	6	464 - 473	10.1093/eurheartj/ehx730	Multicentrico Collaborators